← ANALYST RATINGS · TIPRANKS
Veradermics, Incorporated (MANE): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $165, the highest $170, the lowest $160. The average is +51.3% from the last price of $109.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $115 → $110−4.3% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $112 → $107−4.5% | Hold | −1.7% | Reiterated | 17.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $113 → $109−3.5% | Hold | +0.2% | Reiterated | 17.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $115 → $110−4.3% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $114 → $109−4.4% | Hold | +0.2% | Reiterated | 17.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $116 → $112−3.4% | Hold | +2.9% | Reiterated | 17.10.26on TipRanks 12:05 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $160 | Buy | +47.0% | Reiterated | 15.10.26on TipRanks 07:50 | +1.1%next day −4.3% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $182 | Buy | +67.2% | Reiterated | 08.09.26on TipRanks Sep 10 06:10 | +5.9%next day −3.5% · 5 days +1.2% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $164 | Buy | +50.7% | Reiterated | 12.08.26on TipRanks 14:15 | −0.2%next day +1.1% · 5 days +2.4% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $170 | Buy | +56.2% | Reiterated | 11.08.26on TipRanks 12:49 | −1.3%next day −0.2% · 5 days +2.6% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $170 | Buy | +56.2% | Initiated | 15.07.26on TipRanks 05:35 | +11.9%next day −13.9% · 5 days −10.2% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | $75.00 | Buy | −31.1% | Initiated | 02.03.26on TipRanks 06:45 | +1.6%next day −2.4% · 5 days +11.3% | ↗ |
| Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% | Cantor Fitzgerald | — | Buy | — | Initiated | 01.03.26on TipRanks 12:30 | +1.6%next day −2.4% · 5 days +11.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Veradermics, Incorporated
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $169 at a price of $121 (+39.6%); now: $169 at $109 (+55.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 0 | 2 | 4 | 6 | 4 |
| Buy | 5 | 7 | 9 | 8 | 4 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Veradermics, Incorporated
- CEO: Reid Waldman
- Employees: 37
- 470 James Street, New Haven, CT, 06513, US
- www.veradermics.com
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Data from the stock’s TipRanks forecast page, read 157 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗